OpGen (OPGN) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a report issued on Wednesday.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

A number of other analysts also recently issued reports on OPGN. ValuEngine raised shares of OpGen from a hold rating to a buy rating in a report on Tuesday, July 10th. HC Wainwright set a $8.00 price target on shares of OpGen and gave the stock a buy rating in a report on Friday, August 3rd.

NASDAQ OPGN traded up $0.01 during mid-day trading on Wednesday, reaching $1.33. 75,353 shares of the stock were exchanged, compared to its average volume of 173,372. OpGen has a 1 year low of $1.18 and a 1 year high of $7.60. The company has a market capitalization of $8.20 million, a PE ratio of -0.14 and a beta of 1.94. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.99 and a current ratio of 2.13.

A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC purchased a new position in shares of OpGen Inc (NASDAQ:OPGN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned approximately 0.99% of OpGen as of its most recent filing with the Securities and Exchange Commission (SEC). 11.36% of the stock is currently owned by hedge funds and other institutional investors.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Read More: Should You Consider an Index Fund?

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply